• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Epitope-Specific Antibody Immunodominance Driving Antibody and Influenza Viral Evolution During 2010- 2024

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2025 Jul 25;12(8):ofaf440.
doi: 10.1093/ofid/ofaf440. eCollection 2025 Aug. Epitope-Specific Antibody Immunodominance Driving Antibody and Influenza Viral Evolution During 2010- 2024

Xiuhua Lu[SUP] 1 [/SUP], Feng Liu[SUP] 1 [/SUP], Wen-Pin Tzeng[SUP] 1 [/SUP], Xiao-Yu Zheng[SUP] 1 [/SUP], Terrence M Tumpey[SUP] 1 [/SUP], Ian A York[SUP] 1 [/SUP], Rebecca J Kondor[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP]



Affiliations
Abstract

Background: Understanding hemagglutination inhibition antibody immunodominance (HAI-Ab-ID) is key to forecasting influenza virus antigenic drift and improving vaccine strain selection. We explored epitope-specific HAI-Ab-IDs in adults immunized with A/California/07/2009-like (CA/09) vaccine and A(H1N1)pdm09 viral evolutions.
Methods: Sera from adults (N = 300; birth year, 1961-1998) collected from 2010 to 2016 were analyzed in HAI assays. To determine epitope-specific HAI-Ab-IDs, 4 reverse genetics (RG) viruses were generated: RG-wt possessing CA/09 wild type hemagglutinin and 3 RG mutants containing K163Q, K130 deletion, or D127N/N129T mutations. To analyze cross-reactive or strain-specific HAI-Ab-IDs, 10 historical 1977-2007 A(H1N1) viruses were used. Antibody adsorption assays were used to verify the specificity of HAI-Ab-IDs. Publicly available sequences of A(H1N1)pdm09 viruses from GISAID (Global Initiative on Sharing All Influenza Data; n = 100 277, 2010-2024) were analyzed for viral evolution.
Results: Four HAI-Ab-IDs targeting the epitopes possessing K163, D127 + N129 + K130, K130, or D127 + N129 were detected in >50% donors during 2010 to 2016. Three HAI-Ab-IDs (K163-Ab-IDs, D127/N129/K130-Ab-IDs, and K130-Ab-IDs) cross-inhibited some 1977-2007 viruses. Conversely, D127/N129-Ab-ID showed no cross-inhibition with historical 1977-2007 viruses. Low proportions of K130-Ab-IDs were presented mainly in prevaccination sera. Shifts of cross-reactive HAI-Ab-IDs to strain-specific D127/N129-Ab-ID occurred between 2010 and 2016. The HAI-Ab-IDs exerted immune selection pressures on hemagglutinin (4 positions: D127, N129, K130, and K163). So far, 3 escape mutations became fixed in the 2013-2014 season (K163Q), 2020-2021 season (N129D), and 2022-2023 season (K130N).
Conclusions: HAI-Ab-IDs were common phenomena in adults from 2010 to 2016. Preexisting HAI-Ab-IDs drove viral and antibody evolutions by HAI-Ab-mediated immune selection and suppression. Monitoring viral and HAI-Ab-ID evolution is of great importance to improve vaccine effectiveness.

Keywords: antibody evolution; antibody immunodominance; hemagglutination inhibition antibody; influenza vaccine; viral evolution.

 
Back
Top Bottom